Abstract: The present disclosure provides a strengthened glass and a glass strengthening method, and an electronic device housing. Two opposing sides of the strengthened glass have surface compressive stress layers, and a third stress layer is sandwiched between the two surface compressive stress layers. The third stress layer includes a compressive stress region and multiple tensile stress regions spaced apart within the compressive stress region, the multiple tensile stress regions are extended in a thickness direction of the strengthened glass, and each of the tensile stress regions is surrounded by the compressive stress region. A sum of thicknesses of the surface compressive stress layers and a thickness of the compressive stress region located between two adjacent tensile stress regions is equal to a thickness of the strengthened glass.

Abstract: The present invention provides a fractional order sliding mode synchronous control method for a teleoperation system based on an event trigger mechanism. The method comprises: establishing a dynamics model for the teleoperation system by considering external disturbance and parameter uncertainty, selecting a master robot and a slave robot, interactively establishing the teleoperation system through a communication network, determining system parameters of the dynamics model, designing a fractional order nonsingular rapid terminal sliding mode surface equation by utilizing a position tracking error and a fractional order calculus, setting a trigger event condition of information interaction between the master robot and the slave robot, designing a self-adaptive fractional order nonsingular rapid terminal sliding mode controller based on the sliding mode, designing a Lyapunov function to carry out stability analysis, proving the boundedness of a closed-loop state signal of the system.

Abstract: An anti-Epidermal Growth Factor Receptor (EGFR) and anti-Cluster-of-Differentiation (CD3) bispecific antibody and uses thereof are provided. The bispecific antibody can specifically bind to antigen epidermal growth factor receptor (EGFR) on tumor cell surface and antigen CD3 molecule on immune cell surface. The single-chain antibody (ScFv) of an anti-CD3 antibody is located at the C terminal of the constant region of the anti-EGFR antibody. Further provided are a preparation method of the bispecific antibody and clinical applications of the bispecific antibody. The bispecific antibody has high affinity, and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by other overexpression of the EGFR.

Abstract: An art-Epidermal Growth Factor Receptor (EGFR) and anti-Cluster-of-Differentiation (CD3) bispecific antibody and uses thereof are provided. The bispecific antibody can specifically bind to antigen epidermal growth factor receptor (EGFR) on tumor cell surface and antigen CD3 molecule on immune cell surface. The single-chain antibody (ScFv) of an anti-CD3 antibody is located at the C terminal of the constant region of the anti-EGFR antibody. Further provided are a preparation method of the bispecific antibody and clinical applications of the bispecific antibody. The bispecific antibody has high affinity, and is used for treating tumor diseases caused by high expression or abnormal expression of the EGFR and other diseases caused by other overexpression of the EGFR.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.

Abstract: The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.